March 18, 2025

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

PPMX-T003: Notice on Completion of Clinical Study Report of Phase I Clinical Trial among Polycythemia Vera Patients

Perseus Proteomics Inc. hereby announces that it has completed the clinical study report (CSR) of the Phase I clinical trial of an anti-transferrin receptor 1 antibody, PPMX-T003 (“the Phase I”), among polycythemia vera (“PV”) patients.

The Phase I was conducted with six subjects suffering from PV, a disease characterized by abnormal increase in red blood cells to evaluate safety and pharmacokinetics of PPMX-T003, as well as to confirm its efficacy as secondary endpoints. As a result, no serious adverse events of concern regarding the safety of PPMX-T003 were confirmed and efficacy was indicated with RBC parameters including hematocrit and hemoglobin. Also, a 12-week period without the need for phlebotomy was achieved in 5 subjects except for the sixth subject whose tests were terminated due to personal reasons.

There is no impact on the business result for the fiscal year 2025/3.

END